GRAIL Inc

GRAL

Market cap $2.08B

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "updating our cash-burn guidance further to no more than $290 million for the full year of 2025.

MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, Mar. 3 at 10:30 a.m.

New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "updating our cash-burn guidance further to no more than $290 million for the full year of 2025.

Follow-up data could make the trial's findings look much better than they do now. Management believes the results of the trial won't impact an approval decision by the Food and Drug Administration (FDA) We're bullish on these 10 stocks ›

SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL). If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-grail-inc-investigation-gral.html You can also contact attorney J.C.

The biotech is developing a test to detect multiple cancers. However, a recent clinical trial did not produce the hoped-for results.

Grail's trial missed its primary endpoint, causing a major stock drop. Management is hoping follow-up data will prove more beneficial.

Baker Bros. Advisors increased its stake in GRAIL by 455,208 shares during the fourth quarter; the estimated transaction value was $39.33 million based on quarterly average pricing.

GRAIL Inc. (NASDAQ: GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reducing late-stage cancer diagnoses.

A T206 Honus Wagner baseball card in a family collection for 116 years was sold for $5.124 million at auction, becoming the third-most expensive ever for this specific card.